Yea, assuming an orphan price, which cant be pursued if approval...

Yea, assuming an orphan price, which cant be pursued if approval in DKD is targeted aswell. There are about 2k FGFS patients in America, where the majority of sales will be expected (e.g invokana did 90% in US in peak year). Thats one FSGS patient for every ~3500 DKD patients.If we use the lower end of your assertion and say $100m, thats $50,000 per patient per year. Invokana is about $7k list price per year. If you think any insurance company is going to cover that you're sorely mistaken. Expect pricing appreciably sub-SGLT2s given that these will be needed in addition (as in teh study)I suggest you spend about 30 minutes reading anything about the two diseases, or how drugs are priced